Scisparc Ltd. · NASDAQ:SPRC
Scisparc — Investor Presentation (October 2023)
23 slides from Scisparc's investor presentation, Oct 18, 2023
Slide 1: Corporate Presentation October 2023
CORPORATE PRESENTATION Nasdaq: SPRC October 2023
Slide 2: Forward-looking statements
This presentation of SciSparc Ltd . (the “ Company ” or “ SciSparc ” ) contains “ forward - looking statements ” within the meaning of the Private Securities Litigation Reform Act and other securities laws . Words such as “ expects, ” “ anticipates, ” “ intends, ” “ plans, ” “ believes, ” “ seeks, ”
Slide 3: SciSparc Nasdaq: SPRC highlights
SciSparc NASDAQ: SPRC • 3 programs in advanced clinical trials • Cash and cash equivalents as of June 30, 2023: $2.08 million • Recently raised gross funds of $6.3 million in the equity capital markets • Consumer supplement activity, Wellution TM , generated approximately $2 million in revenues fo
Slide 4: Pharma programs and consumer supplement activity
Pharma programs Autism Spectrum Disorder (ASD) Tourette Syndrome (TS) - Phase IIb Alzheime r ’ s Diseas e (AD) and agitation - Phase IIa SciSparc Nutraceuticals Inc. Consumer supplement activity ~ 51 % Platform SCI - 210 CBD (Cannabidiol) + CannAmide TM TM SciSparc Ltd. Clinical stages Platform
Slide 5: Own strong IP portfolio
Ow n s t r ong IP portfolio 9 patent families ϭϱ granted patents ( ϳ in the U.S.) Additional pending patent applications ( Europe, China Japan and more) INTELLECTUAL PROPERTY
Slide 6: Our methodology: CannAmide combined with cannabinoids
Utilizing the Endocannabinoid system to affect the central nervous system (CNS) Combining CannAmide TM * with Different cannabinoids Formulation Ideal solution Reducing cannabinoids doses Maintaining therapeutic efficacy Increasing safety OUR METHODOLOGY * CannAmide TM - SciSparc proprietary formula
Slide 7: Market opportunity
Status Epilepticus The global epilepsy market size would grow from $ ϭϬ .6 B in 20 Ϯϭ to $ 14.9 B In 2031 ** Pain and Inflammation The global chronic pain treatment market was estimated at US$ 81.36 billion in 2021 and is expected to surpass a valuation of US$ 191.61 billion by 2030 ***** Alzheime
Slide 8: 2023 achievements
2023 ACHIEVEMENTS Initiated our clinical trial with SCI - 210 in pediatrics with Autism Spectrum Disorder at the Soroka Medical Center Announced initiation of randomized Phase IIb clinical trial of our proprietary SCI - 110 for Tourette Syndrome Granted an exclusive license for the sales of CannAmid
Slide 9: Pharmaceutical pipeline status
PHASE IIa C OMPOUN D THERAPEUTI C AR E A PR E CLINICA L PHASE I PHASE IIa PHASE IIb PHASE IIb PHASE III PHASE III SCI - 110 – Proprietary combination of T etrahydrocannabinol (THC) with CannAmide SCI - 210 – Proprietary combination of Cannabidiol (CBD) with CannAmide SCI - 160 – Proprietary CB 2 R a
Slide 10: SCI-110 for Tourette Syndrome (TS) Phase IIa
SCI - 110 for T OURE T T E S YND R OM E (TS) PHASE IIA Led by Child Study Center at Yale University About : TS is a movement and neurobehavioral disorder characterized by motor and vocal tics and is highly linked with co - morbidities As the currently used medications are managing only a small numbe
Slide 11: SCI-110 for TS Phase IIb
SCI - 110 for TS PHASE IIB • Objective: to evaluate the efficacy, safety and tolerability of the Company ’ s proprietary SCI - 110 in a randomized, double - blind, placebo controlled, cross - over study • Three leading medical centers: Yale Child Study Center at Yale University, Hannover Medical Sch
Slide 12: SCI-110 for Alzheimer's Disease & Agitation Phase IIa
SCI - 110 for ALZHEIMER ’ S DISEASE (AD) & AGITATION Phase IIA Objective: to evaluate the safety, tolerability and efficacy trend of SCI - 110 in an open label study in patients with Alzheimer Disease (AD) and Agitation • P ositive final results meeting primary and secondary endpoints at Phase IIa
Slide 13: SCI-210 for Autism Spectrum Disorder (ASD)
• Study objective: to evaluate the safety, tolerability and efficacy of SCI - 210 in children with ASD in a randomized, double - blind, placebo controlled with cross - over study • Study site: the Clinical Research Center and Negev Autism Center and Soroka University Medical Center, Be'er - Sheva, I
Slide 14: Psychedelics collaboration with Clearmind Medicine
Psychedelics collaboration with Clearmind Medicine
Slide 15: SciSparc-Clearmind collaboration
SCISPARC - CLEARMIND COLLABORATION SciSparc ’ s CannAmide Ρ and Clearmind ’ s MEAI The collaboration includes examination of the benefit of integrating the core technologies of each company for the development of innovative psychedelic - centric drug candidates targeting addiction treatment and ment
Slide 16: Indications: Alcohol Use Disorder
INDICATIONS Alcohol Use Disorder (AUD) Alcohol consumption contributes to 3 million deaths each year globally... ... In addition to disabilities and poor health of millions of people World Health Organization Initial pre - clinical results in treating AUD > Pre - clinical trials based on the proprie
Slide 17: Top Seller of American Food Supplements and Cosmetics Brand on Amazon.com
Top Seller of American Food Supplements and Cosmetics Brand on Amazon. com
Slide 18: Wellution
Wellution Ρ SciSparc Nutraceuticals Inc., a majority - owned subsidiary of SciSparc Ltd. (~ 51 %) , holds the Amazon Marketplace account, American food supplements and cosmetics brand and trademark of Wellution Wellution Ρ is strong health and beauty brand selling on Amazon US which was established
Slide 19: Products
es Products died Natural Supplements Natural Creams & Gel S We! dion
Slide 20: Management team
O z Adler C E O , C F O Mr. Adler has experience in a wide variety of managerial, financial, tax and accounting practices. From 2012 to 2017 , Mr. Adler was employed as a certified public accountant at Kost Forer Gabbay & Kasierer , a member of Ernst & Young Global. Mr. Adler holds a B.A. degree in
Slide 21: SciSparc Scientific Advisory Board
SCISPARC SCIENTIFIC ADVISORY BOARD Award winning scientists Ϯϭ Prof. James Leckman A child Psychiatrist at Yale University S erved as Director of the Child Study Center at Yale for over two decades A prominent international expert in the field of research and treatment of Tourette Syndrome Prof. Kir
Slide 22: Summary
SUMMARY Proprietary Technology with cutting - edge drug combinations addressing large global unmet medical needs Two Phase 2 Assets addressing multi - billion markets and a Pending Phase 3 * Clinical Trial Positive final results meeting primary and secondary endpoints at Phase IIa study in AD patien
Slide 23: Thank You
Thank You Investor Contact: IR@scisparc.com Tel: + 972 - 3 - 6167055 https://scisparc.com/